Total Payments
$45,749
2024 Payments
$16,455
Companies
24
Transactions
177
Medicare Patients
8,720
Medicare Billing
$9.1M
Payment Breakdown by Category
Consulting$27,488 (60.1%)
Other$11,959 (26.1%)
Food & Beverage$5,612 (12.3%)
Travel$641.56 (1.4%)
Education$49.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $27,488 | 15 | 60.1% |
| Honoraria | $6,390 | 3 | 14.0% |
| Food and Beverage | $5,612 | 148 | 12.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,569 | 7 | 12.2% |
| Travel and Lodging | $641.56 | 3 | 1.4% |
| Education | $49.00 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch & Lomb Americas Inc. | $15,118 | 32 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $10,949 | 21 | $0 (2024) |
| Genentech USA, Inc. | $8,094 | 13 | $0 (2024) |
| Alimera Sciences, Inc. | $6,580 | 10 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $2,393 | 5 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $725.33 | 28 | $0 (2024) |
| ABBVIE INC. | $356.59 | 14 | $0 (2024) |
| Allergan, Inc. | $335.78 | 15 | $0 (2022) |
| Mallinckrodt Hospital Products Inc. | $183.92 | 6 | $0 (2024) |
| ShockWave Medical, Inc | $160.38 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,455 | 42 | Genentech USA, Inc. ($8,069) |
| 2023 | $7,820 | 43 | Bausch & Lomb Americas Inc. ($5,041) |
| 2022 | $11,253 | 36 | Bausch & Lomb Americas Inc. ($5,648) |
| 2021 | $2,768 | 11 | EyePoint Pharmaceuticals US, Inc. ($1,780) |
| 2020 | $1,567 | 4 | Bausch & Lomb, a division of Bausch Health US, LLC ($1,500) |
| 2019 | $5,469 | 20 | Alimera Sciences, Inc. ($5,081) |
| 2018 | $168.78 | 8 | Vyera Pharmaceuticals, LLC ($96.63) |
| 2017 | $248.10 | 13 | Mallinckrodt LLC ($125.58) |
All Payment Transactions
177 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $29.93 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/14/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug), VISUDYNE | Food and Beverage | In-kind items and services | $22.26 | General |
| Category: Ophthalmology | ||||||
| 12/14/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug), VISUDYNE | Food and Beverage | In-kind items and services | $1.75 | General |
| Category: Ophthalmology | ||||||
| 12/07/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $31.91 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/05/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $127.31 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/05/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/05/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $1.51 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/04/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $34.00 | General |
| Category: Ophthalmology | ||||||
| 11/23/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $37.80 | General |
| Category: Ophthalmology | ||||||
| 11/07/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Ophthalmology | ||||||
| 11/02/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,860.00 | General |
| 11/02/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $267.93 | General |
| 11/02/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $193.63 | General |
| 11/02/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $180.00 | General |
| 11/02/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $129.58 | General |
| 11/02/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $98.57 | General |
| 11/02/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $85.46 | General |
| 11/02/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $74.57 | General |
| 10/23/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $29.76 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 10/20/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Consulting Fee | Cash or cash equivalent | $1,387.50 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 10/20/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | In-kind items and services | $184.06 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 10/18/2024 | Bausch & Lomb Americas Inc. | — | Food and Beverage | In-kind items and services | $130.17 | General |
| 09/27/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/19/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 09/04/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: OPHTHALMOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,033 | 8,897 | $9.2M | $2.3M |
| 2022 | 15 | 2,121 | 9,177 | $6.1M | $2.4M |
| 2021 | 15 | 2,266 | 10,097 | $5.7M | $2.3M |
| 2020 | 15 | 2,300 | 9,504 | $5.2M | $2.1M |
Total Patients
8,720
Total Services
37,675
Medicare Billing
$9.1M
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 201 | 2,320 | $6.2M | $1.6M | 25.5% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 42 | 1,563 | $1.2M | $280,579 | 23.2% |
| 67028 | Injection of drug into eye | Office | 2023 | 277 | 1,231 | $578,688 | $123,543 | 21.3% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 530 | 1,138 | $450,648 | $104,637 | 23.2% |
| 92134 | Imaging of retina | Office | 2023 | 604 | 1,954 | $248,158 | $59,311 | 23.9% |
| J3590 | Unclassified biologics | Office | 2023 | 12 | 22 | $145,488 | $39,921 | 27.4% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 11 | 154 | $85,470 | $24,378 | 28.5% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 11 | 104 | $87,360 | $22,530 | 25.8% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 11 | 11 | $42,219 | $10,504 | 24.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 70 | 95 | $38,000 | $9,476 | 24.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 54 | 63 | $24,822 | $6,625 | 26.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 43 | 43 | $22,403 | $5,556 | 24.8% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 41 | 41 | $19,229 | $4,433 | 23.1% |
| 92250 | Photography of the retina | Office | 2023 | 84 | 101 | $11,716 | $2,659 | 22.7% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 15 | 22 | $9,510 | $2,066 | 21.7% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 15 | 18 | $5,040 | $1,305 | 25.9% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 12 | 17 | $2,567 | $659.67 | 25.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 227 | 2,248 | $3.5M | $1.6M | 45.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 78 | 1,793 | $1.1M | $405,998 | 37.3% |
| 67028 | Injection of drug into eye | Office | 2022 | 302 | 1,261 | $679,442 | $124,991 | 18.4% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 545 | 1,195 | $264,512 | $110,434 | 41.8% |
| 92134 | Imaging of retina | Office | 2022 | 637 | 1,978 | $290,462 | $60,481 | 20.8% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2022 | 13 | 252 | $139,860 | $39,774 | 28.4% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 53 | 58 | $16,804 | $5,553 | 33.0% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 47 | 47 | $11,785 | $5,212 | 44.2% |
About Dr. Christopher Henry, MD
Dr. Christopher Henry, MD is a Ophthalmology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/20/2009. The National Provider Identifier (NPI) number assigned to this provider is 1881837995.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Henry, MD has received a total of $45,749 in payments from pharmaceutical and medical device companies, with $16,455 received in 2024. These payments were reported across 177 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($27,488).
As a Medicare-enrolled provider, Henry has provided services to 8,720 Medicare beneficiaries, totaling 37,675 services with total Medicare billing of $9.1M. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Uveitis and Ocular Inflammatory Disease
- Location Houston, TX
- Active Since 04/20/2009
- Last Updated 03/29/2017
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1881837995
Products in Payments
- XIPERE (Drug) $17,262
- YUTIQ (Drug) $6,920
- Iluvien (Drug) $5,081
- EYP-1901 (Drug) $3,370
- ILUVIEN (Drug) $1,390
- OZURDEX (Drug) $645.33
- EYP-1901 $485.66
- EYLEA (Biological) $413.83
- EYLEA HD (Biological) $365.76
- ACTHAR (Biological) $323.55
- DEXYCU (Drug) $282.65
- Vabysmo (Drug) $204.04
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter (Device) $160.38
- RETISERT (Drug) $136.17
- Daraprim Tablet 25mg (Drug) $96.63
- EYLEA AFLIBERCEPT INJECTION (Biological) $72.85
- Izervay (Drug) $64.37
- Cimerli (Biological) $59.12
- FlowTriever (Device) $54.85
- HUMIRA (Biological) $47.04
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Houston
Stephen Slade, M.d, M.D
Ophthalmology — Payments: $1.5M
Ophthalmology $1.5M
Dr. Christina Weng, M.d., M.b.a, M.D., M.B.A
Ophthalmology — Payments: $635,330
Ophthalmology $635,330
Zaina Al-Mohtaseb, Md, MD
Ophthalmology — Payments: $559,665
Ophthalmology $559,665
Dr. John Micheletti, M.d, M.D
Ophthalmology — Payments: $555,738
Ophthalmology $555,738
David Brown, M.d, M.D
Ophthalmology — Payments: $488,095
Ophthalmology $488,095
Dr. Douglas Koch, M.d, M.D
Ophthalmology — Payments: $457,260
Ophthalmology $457,260